Next-Generation Antibody Therapeutics Market Report 2025

The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $6.82 billion in 2024 to $7.63 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to monoclonal antibody success, rising prevalence of chronic diseases, approval of antibody-drug conjugates, growth of immunotherapy, gene therapy and antibodies.

The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $11.52 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to biosimilar development, bispecific antibodies development, nanobody development, patient-centric approaches, immunomodulatory antibodies, expanded applications in autoimmune diseases, continuous manufacturing. Major trends in the forecast period include advancements in antibody engineering, digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, real-world evidence in antibody development.

The anticipated rise in the prevalence of chronic diseases is poised to drive the growth of the next-generation antibody therapeutics market. Chronic diseases, enduring for a year or more, necessitate continuous medical care and often restrict daily activities. Next-generation antibody therapeutics play a pivotal role in offering targeted care for individuals with chronic illnesses, contributing to improved patient outcomes. As per projections from the National Center for Biotechnology Information (NCBI) in January 2023, the number of individuals aged 50 and older with at least one chronic illness is expected to surge by 99.5% by the year 2050, reaching 142.66 million. This underscores the pivotal role of next-generation antibody therapeutics in addressing the escalating prevalence of chronic diseases.

The increasing demand for pharmaceutical companies is set to propel the growth of the next-generation antibody therapeutics market. With a focus on drug discovery, development, production, and marketing, the pharmaceutical industry plays a crucial role in healthcare. Next-generation antibody therapeutics offer advantages such as improved targeting precision, reduced side effects, personalized medicine, extended half-life, dosage interval innovations, multifunctional antibodies, and optimized manufacturing processes. In June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $384.2 billion (€340,000 million) in 2022, marking a 4.95% increase from 2021. This underscores the growing demand for pharmaceutical companies, thereby driving the next-generation antibody therapeutics market.

Technological advancements are a significant trend gaining traction in the next-generation antibody therapeutics market. Major companies in this field are focusing on developing innovations like proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to enhance protein identification and characterization, resulting in more targeted and effective treatments. These advancements are intended to improve therapeutic profiles, reduce costs, and tackle complex diseases with greater precision. MIPSA technology organizes protein molecules into structured assemblies for better analysis and quantification, increasing sensitivity and accuracy in protein detection, which is beneficial for research and diagnostics. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology firm, launched a next-generation antibody profiling platform that employs MIPSA technology for high-throughput, cost-effective analysis of immune responses, with the goal of improving disease understanding and personalizing treatment strategies.

Collaborations and partnerships are strategic trends gaining traction in the next-generation antibody therapeutics market. Such collaborations facilitate innovation, harness complementary expertise, and expedite the development and commercialization of advanced therapies. In December 2023, AbbVie Inc., a US-based pharmaceutical company, collaborated with BigHat Biosciences, a protein therapeutics company, to leverage machine learning (ML) and artificial intelligence (AI) for discovering therapeutic antibodies. This collaboration aims to advance the development of next-generation therapeutic antibodies through BigHat Biosciences' Milliner platform, combining ML technologies with a high-speed wet lab for antibody design and selection.

In October 2022, AbbVie, a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based developer of therapeutic monoclonal antibodies. This strategic acquisition enhances AbbVie's antibody research initiatives, expands its immunology portfolio, and strengthens its position in Oxford's thriving bioscience sector.

Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Next-generation antibody therapeutics represent a class of advanced antibody-based drugs characterized by enhanced structures, functionalities, and therapeutic potential beyond traditional monoclonal antibodies. These therapeutics are employed to address severe medical conditions, including cancer, infectious infections, and immunological disorders.

The main types of antibodies in next-generation antibody therapeutics include monoclonal antibodies, polyclonal antibodies, biospecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-produced proteins designed to bind to specific targets, such as antigens on the surface of cancer cells. These therapeutics find applications across various therapeutic areas, including oncology, autoimmune diseases, infectious diseases, neurodegenerative disorders, and others. They are utilized in hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other relevant entities.

The next-generation antibody therapeutics market research report is one of a series of new reports that provides next-generation antibody therapeutics market statistics, including next-generation antibody therapeutics industry global market size, regional shares, competitors with a next-generation antibody therapeutics market share, detailed next-generation antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation antibody therapeutics industry. This next-generation antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation antibody therapeutics market consists of revenues earned by entities by providing services such as antibody engineering, antibody manufacturing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation antibody therapeutics market also includes sales of immune checkpoint inhibitors, antibody-targeted nanoparticles, and antibody-mimetic proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.